NPPA and acute kidney injury: Kurnik et al. [180] performed a multicenter, prospective, randomized, double-blind, and placebo-controlled trial to evaluate the efficacy of i.v. atrial natriuretic peptide (anaritide, ANP 4–28) to prevent contrast-induced AKI in patients with SCr >1.8 mg/dL or eGFR of ≤65 mL/min.